vs

Side-by-side financial comparison of Baird Medical Investment Holdings Ltd (BDMD) and TECHPRECISION CORP (TPCS). Click either name above to swap in a different company.

Baird Medical Investment Holdings Ltd is the larger business by last-quarter revenue ($8.0M vs $7.1M, roughly 1.1× TECHPRECISION CORP). TECHPRECISION CORP runs the higher net margin — -20.8% vs -142.7%, a 121.9% gap on every dollar of revenue. TECHPRECISION CORP produced more free cash flow last quarter ($-827.0K vs $-3.2M).

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.

BDMD vs TPCS — Head-to-Head

Bigger by revenue
BDMD
BDMD
1.1× larger
BDMD
$8.0M
$7.1M
TPCS
Higher net margin
TPCS
TPCS
121.9% more per $
TPCS
-20.8%
-142.7%
BDMD
More free cash flow
TPCS
TPCS
$2.4M more FCF
TPCS
$-827.0K
$-3.2M
BDMD

Income Statement — Q2 FY2025 vs Q3 FY2026

Metric
BDMD
BDMD
TPCS
TPCS
Revenue
$8.0M
$7.1M
Net Profit
$-11.4M
$-1.5M
Gross Margin
82.1%
5.4%
Operating Margin
-131.3%
-19.1%
Net Margin
-142.7%
-20.8%
Revenue YoY
-6.9%
Net Profit YoY
-84.4%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDMD
BDMD
TPCS
TPCS
Q4 25
$7.1M
Q3 25
$9.1M
Q2 25
$8.0M
$7.4M
Q1 25
$9.5M
Q4 24
$7.6M
Q3 24
$8.9M
Q2 24
$8.0M
Q1 24
$8.6M
Net Profit
BDMD
BDMD
TPCS
TPCS
Q4 25
$-1.5M
Q3 25
$825.0K
Q2 25
$-11.4M
$-597.0K
Q1 25
$112.0K
Q4 24
$-799.0K
Q3 24
$-601.0K
Q2 24
$-1.5M
Q1 24
$-5.1M
Gross Margin
BDMD
BDMD
TPCS
TPCS
Q4 25
5.4%
Q3 25
27.1%
Q2 25
82.1%
14.0%
Q1 25
22.0%
Q4 24
13.0%
Q3 24
11.3%
Q2 24
3.0%
Q1 24
14.3%
Operating Margin
BDMD
BDMD
TPCS
TPCS
Q4 25
-19.1%
Q3 25
10.4%
Q2 25
-131.3%
-6.3%
Q1 25
3.9%
Q4 24
-9.1%
Q3 24
-5.5%
Q2 24
-16.8%
Q1 24
-28.6%
Net Margin
BDMD
BDMD
TPCS
TPCS
Q4 25
-20.8%
Q3 25
9.1%
Q2 25
-142.7%
-8.1%
Q1 25
1.2%
Q4 24
-10.5%
Q3 24
-6.7%
Q2 24
-18.3%
Q1 24
-59.5%
EPS (diluted)
BDMD
BDMD
TPCS
TPCS
Q4 25
$-0.15
Q3 25
$0.08
Q2 25
$-0.06
Q1 25
$0.01
Q4 24
$-0.08
Q3 24
$-0.06
Q2 24
$-0.16
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDMD
BDMD
TPCS
TPCS
Cash + ST InvestmentsLiquidity on hand
$50.0K
Total DebtLower is stronger
$8.4M
Stockholders' EquityBook value
$35.6M
$8.0M
Total Assets
$77.0M
$32.8M
Debt / EquityLower = less leverage
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDMD
BDMD
TPCS
TPCS
Q4 25
$50.0K
Q3 25
$220.0K
Q2 25
$143.0K
Q1 25
$195.0K
Q4 24
$165.0K
Q3 24
$132.0K
Q2 24
$44.8K
Q1 24
$138.0K
Total Debt
BDMD
BDMD
TPCS
TPCS
Q4 25
Q3 25
Q2 25
$8.4M
Q1 25
$3.0K
Q4 24
$19.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BDMD
BDMD
TPCS
TPCS
Q4 25
$8.0M
Q3 25
$9.1M
Q2 25
$35.6M
$8.2M
Q1 25
$8.7M
Q4 24
$8.1M
Q3 24
$8.9M
Q2 24
$7.9M
Q1 24
$7.8M
Total Assets
BDMD
BDMD
TPCS
TPCS
Q4 25
$32.8M
Q3 25
$33.8M
Q2 25
$77.0M
$32.1M
Q1 25
$33.5M
Q4 24
$32.2M
Q3 24
$35.0M
Q2 24
$35.7M
Q1 24
$34.7M
Debt / Equity
BDMD
BDMD
TPCS
TPCS
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDMD
BDMD
TPCS
TPCS
Operating Cash FlowLast quarter
$-3.2M
$183.0K
Free Cash FlowOCF − Capex
$-3.2M
$-827.0K
FCF MarginFCF / Revenue
-40.7%
-11.7%
Capex IntensityCapex / Revenue
0.6%
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDMD
BDMD
TPCS
TPCS
Q4 25
$183.0K
Q3 25
$-1.1M
Q2 25
$-3.2M
$646.0K
Q1 25
$396.0K
Q4 24
$-570.0K
Q3 24
$-532.0K
Q2 24
$107.0K
Q1 24
$-452.0K
Free Cash Flow
BDMD
BDMD
TPCS
TPCS
Q4 25
$-827.0K
Q3 25
$-2.1M
Q2 25
$-3.2M
$-604.0K
Q1 25
$-930.0K
Q4 24
$-1.7M
Q3 24
$-2.0M
Q2 24
$-94.0K
Q1 24
$-900.0K
FCF Margin
BDMD
BDMD
TPCS
TPCS
Q4 25
-11.7%
Q3 25
-22.9%
Q2 25
-40.7%
-8.2%
Q1 25
-9.8%
Q4 24
-22.9%
Q3 24
-21.8%
Q2 24
-1.2%
Q1 24
-10.5%
Capex Intensity
BDMD
BDMD
TPCS
TPCS
Q4 25
14.2%
Q3 25
11.0%
Q2 25
0.6%
16.9%
Q1 25
14.0%
Q4 24
15.4%
Q3 24
15.9%
Q2 24
2.5%
Q1 24
5.2%
Cash Conversion
BDMD
BDMD
TPCS
TPCS
Q4 25
Q3 25
-1.31×
Q2 25
Q1 25
3.54×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDMD
BDMD

Segment breakdown not available.

TPCS
TPCS

Defense$6.7M94%
Other$410.0K6%

Related Comparisons